Trader Note — 2287 total
AVGO has done something remarkable over the past month: it has gained 36% while the broader semiconductor complex has been grappling with tariff noise and macro uncertainty. The stock closed at $427.36 on Tuesday, up…
Hamilton Insurance Group enters the week down 6.5% — the biggest talking point for the stock right now is the gap between that price drop and an analyst community that just raised targets. The Street's reaction to Q1…
GRAL enters the post-earnings week in an interesting position: the stock beat Q1 estimates, absorbed a 2.3% single-day pullback, and yet short sellers barely flinched — leaving a meaningful short position intact…
Viemed Healthcare walked into its Q1 2026 earnings print carrying a 3.5% weekly loss and walked out with a 2.3% bounce — a tidy illustration of how much was already priced for caution before the numbers dropped. Q1…
GD Culture Group enters its May 15 earnings with a remarkable price run at its back — and short sellers quietly stepping aside. The stock has doubled over the past month, closing at $5.99 on May 5. That +22% single-day…
Hyperion DeFi heads into its May 11 earnings report with a fresh equity raise landing squarely on top of a 44% one-month rally and a short base that has halved since April. The timing of the capital raise is the…
One Stop Systems just put its best quarterly beat on record — and the stock still has active shorts building positions heading into the reaction. Q1 2026 adj. EPS of $0.01 crushed the $(0.04) consensus estimate.…
Red Violet just delivered the clearest signal it has given investors all year — a Q1 earnings beat that landed after the close on May 6, with the stock already up 6% on the week heading into the print. The numbers were…
InflaRx enters its May 7 results carrying a month-long price surge and a borrow market that has quietly loosened — a setup that puts the clinical pipeline firmly in the spotlight. The stock's 116% one-month gain to…
Angi Inc. files its Q1 2026 results on May 6, catching a stock that is 43% lower year-to-date and carrying a short interest load that has just turned a corner. Short sellers have been paring exposure for five weeks…
ROKU enters the second week of May with one of the most divergent setups in the streaming sector — a stock up 27% over the past month that's simultaneously attracting upgrades from nearly every analyst on the Street…
JAGX has entered an extraordinary stretch of dislocation — the stock is down 64% on the week and nearly 79% over the past month, trading at $3.01 after a brutal post-reverse-split unwind that has compressed the market…
Granite Point Mortgage Trust heads into its June earnings cycle trading at $1.42 — well below the analyst consensus target of $2.05 — with the Street divided and the lending market relaxed, even as short interest…
MTCH just delivered a Q1 earnings beat that moved the analyst community in one direction — upward — yet the consensus remains far from uniformly bullish. The clearest story this week is the analyst response to…
Olenox Industries enters the week carrying two simultaneous shocks: a subsidiary bankruptcy and a confirmed reverse stock split — and short sellers have been covering fast. The most striking move in the data is the…
UroGen Pharma heads into its May 11 earnings report with short sellers pulling back even as the stock's structural bear case remains firmly intact. The most striking feature of the past month is the divergence between…
Viridian Therapeutics enters its May 7 earnings call riding one of the sharpest weekly moves in the biotech universe — up 38% in five sessions to $18.75, with a single-day gain of 33% on May 5 doing almost all the…
Adient reported Q2 fiscal 2026 earnings on May 6, landing into a market where six weeks of short covering have materially changed the positioning picture. Short sellers have been in steady retreat. Short interest as a…
ABI just delivered its most rewarding single day in months — and the borrow market has taken notice. Q1 results dropped on May 5, and they were unambiguously strong. Revenue hit $15.27 billion, up from $13.63 billion…
Protagonist Therapeutics enters the post-earnings window with a meaningful gap between what the numbers delivered and what the options market had priced for disaster. The company reported Q1 2026 results on May 5,…
